vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Dine Brands Global, Inc.（DIN）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Dine Brands Global, Inc.的1.9倍（$406.6M vs $217.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs -5.6%，领先66.1%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 6.3%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $-8.6M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 2.7%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
戴恩品牌全球公司是一家总部位于美国加利福尼亚州帕萨迪纳的上市餐饮企业，其前身是1958年成立的IHOP。目前公司旗下拥有三个餐饮品牌，分别是Applebee's社区烧烤酒吧、国际煎饼屋（IHOP）和Fuzzy's塔可店，运营特许加盟及直营全服务餐厅。
BCRX vs DIN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $217.6M |
| 净利润 | $245.8M | $-12.2M |
| 毛利率 | 97.7% | 42.4% |
| 营业利润率 | 64.0% | -7.6% |
| 净利率 | 60.5% | -5.6% |
| 营收同比 | 209.1% | 6.3% |
| 净利润同比 | 1017.5% | -336.1% |
| 每股收益（稀释后） | $1.13 | $-0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $217.6M | ||
| Q3 25 | $159.4M | $216.2M | ||
| Q2 25 | $163.4M | $230.8M | ||
| Q1 25 | $145.5M | $214.8M | ||
| Q4 24 | $131.5M | $204.8M | ||
| Q3 24 | $117.1M | $195.0M | ||
| Q2 24 | $109.3M | $206.3M | ||
| Q1 24 | $92.8M | $206.2M |
| Q4 25 | $245.8M | $-12.2M | ||
| Q3 25 | $12.9M | $7.3M | ||
| Q2 25 | $5.1M | $13.8M | ||
| Q1 25 | $32.0K | $8.2M | ||
| Q4 24 | $-26.8M | $5.2M | ||
| Q3 24 | $-14.0M | $19.1M | ||
| Q2 24 | $-12.7M | $23.2M | ||
| Q1 24 | $-35.4M | $17.5M |
| Q4 25 | 97.7% | 42.4% | ||
| Q3 25 | 98.6% | 39.1% | ||
| Q2 25 | 98.3% | 40.0% | ||
| Q1 25 | 96.9% | 42.0% | ||
| Q4 24 | 95.4% | 41.7% | ||
| Q3 24 | 97.3% | 47.8% | ||
| Q2 24 | 98.4% | 48.1% | ||
| Q1 24 | 98.6% | 47.2% |
| Q4 25 | 64.0% | -7.6% | ||
| Q3 25 | 18.6% | 4.7% | ||
| Q2 25 | 18.2% | 8.2% | ||
| Q1 25 | 14.6% | 6.0% | ||
| Q4 24 | -3.4% | 3.8% | ||
| Q3 24 | 6.6% | 13.6% | ||
| Q2 24 | 8.0% | 15.1% | ||
| Q1 24 | -15.6% | 11.7% |
| Q4 25 | 60.5% | -5.6% | ||
| Q3 25 | 8.1% | 3.4% | ||
| Q2 25 | 3.1% | 6.0% | ||
| Q1 25 | 0.0% | 3.8% | ||
| Q4 24 | -20.4% | 2.5% | ||
| Q3 24 | -12.0% | 9.8% | ||
| Q2 24 | -11.6% | 11.2% | ||
| Q1 24 | -38.1% | 8.5% |
| Q4 25 | $1.13 | $-0.79 | ||
| Q3 25 | $0.06 | $0.48 | ||
| Q2 25 | $0.02 | $0.89 | ||
| Q1 25 | $0.00 | $0.53 | ||
| Q4 24 | $-0.13 | $0.35 | ||
| Q3 24 | $-0.07 | $1.24 | ||
| Q2 24 | $-0.06 | $1.50 | ||
| Q1 24 | $-0.17 | $1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $128.2M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $-119.2M | $-273.9M |
| 总资产 | $514.2M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $128.2M | ||
| Q3 25 | $212.9M | $167.9M | ||
| Q2 25 | $260.0M | $194.2M | ||
| Q1 25 | $295.1M | $186.5M | ||
| Q4 24 | $320.9M | $186.7M | ||
| Q3 24 | $96.8M | $169.6M | ||
| Q2 24 | $78.4M | $153.5M | ||
| Q1 24 | $84.3M | $145.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $-119.2M | $-273.9M | ||
| Q3 25 | $-387.9M | $-231.9M | ||
| Q2 25 | $-421.6M | $-212.5M | ||
| Q1 25 | $-451.9M | $-215.7M | ||
| Q4 24 | $-475.9M | $-216.0M | ||
| Q3 24 | $-468.6M | $-216.7M | ||
| Q2 24 | $-475.6M | $-231.7M | ||
| Q1 24 | $-476.2M | $-244.8M |
| Q4 25 | $514.2M | $1.7B | ||
| Q3 25 | $446.4M | $1.8B | ||
| Q2 25 | $457.2M | $1.8B | ||
| Q1 25 | $480.0M | $1.8B | ||
| Q4 24 | $490.4M | $1.8B | ||
| Q3 24 | $491.3M | $1.7B | ||
| Q2 24 | $472.4M | $1.7B | ||
| Q1 24 | $467.9M | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $5.7M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $-8.6M |
| 自由现金流率自由现金流/营收 | 71.6% | -3.9% |
| 资本支出强度资本支出/营收 | 0.2% | 6.6% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | $53.4M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $5.7M | ||
| Q3 25 | $41.6M | $30.2M | ||
| Q2 25 | $41.3M | $37.0M | ||
| Q1 25 | $-27.5M | $16.1M | ||
| Q4 24 | $-5.2M | $30.5M | ||
| Q3 24 | $8.2M | $25.5M | ||
| Q2 24 | $-1.4M | $21.6M | ||
| Q1 24 | $-53.7M | $30.6M |
| Q4 25 | $291.2M | $-8.6M | ||
| Q3 25 | $40.3M | $18.1M | ||
| Q2 25 | $41.1M | $31.0M | ||
| Q1 25 | $-27.7M | $12.8M | ||
| Q4 24 | $-5.9M | $26.7M | ||
| Q3 24 | $8.2M | $22.0M | ||
| Q2 24 | $-1.5M | $18.2M | ||
| Q1 24 | $-53.9M | $27.2M |
| Q4 25 | 71.6% | -3.9% | ||
| Q3 25 | 25.3% | 8.4% | ||
| Q2 25 | 25.2% | 13.4% | ||
| Q1 25 | -19.0% | 6.0% | ||
| Q4 24 | -4.5% | 13.0% | ||
| Q3 24 | 7.0% | 11.3% | ||
| Q2 24 | -1.4% | 8.8% | ||
| Q1 24 | -58.1% | 13.2% |
| Q4 25 | 0.2% | 6.6% | ||
| Q3 25 | 0.8% | 5.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.5% | 1.9% | ||
| Q3 24 | 0.1% | 1.8% | ||
| Q2 24 | 0.1% | 1.7% | ||
| Q1 24 | 0.3% | 1.6% |
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | 4.12× | ||
| Q2 25 | 8.12× | 2.68× | ||
| Q1 25 | -859.91× | 1.97× | ||
| Q4 24 | — | 5.88× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 1.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
